RxDoctor Payments Data

Alexander Lemmer, MD

Transplant Hepatology · Atlanta, GANPI 1104168681

Payments from drug & device makers

$51,008in general payments, 2019–2025

Across 143 payments — averaging $356.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$24K
  • Boehringer Ingelheim International GmbH$20K
  • Boston Scientific$3K
  • Gilead$704
  • Intercept Pharmaceuticals, Inc.$435
  • Madrigal Pharmaceuticals$378
  • plus $1K from 14 others

What the payments were for

  • Speaking & faculty fees$2,02532%
  • Food & beverage$4,21668%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant hepatology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$57,295
Medicare patients
215
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin74$243,625
VemlidyTenofovir Alafenamide43$78,815
Ursodiol130$16,751
Tacrolimus80$14,642
EliquisApixaban19$12,182
Mycophenolate Mofetil88$6,619
Azathioprine65$5,064
Cyclosporine ModifiedCyclosporine, Modified25$4,300
Budesonide EcBudesonide12$2,503
Lactulose64$1,902
Bumetanide73$1,692
Spironolactone123$1,391
Eplerenone13$923
ConstuloseLactulose22$597
Pantoprazole Sodium57$545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$207$243,62574 claims
GileadVemlidy$704$78,81543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few transplant hepatology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other transplant hepatology in Atlanta

Where these figures come from

Is this you, or does something look wrong? →